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7ABSTRACT
Type 2 diabetes mellitus is a health problem worldwide that requires the search for 
novel therapeutic strategies. Natural products are a source of potential therapies 
due to their acceptation and traditional use or consumption. This study aims to 
evaluate selected Bolivian traditionally consumed plants as potential antidiabetic 
products using animal models. Besides, focused on the urinary tract infection, as 
one common complication in diabetes, the antibacterial effect was evaluated in 
the uroepithelial in vitro infection. 
Initially, the screening of glycemia-reducing effect, performed in healthy Swiss 
albino mice, showed that the hydroethanolic extracts of Amaranthus caudatus, 
Chenopodium quinoa, Lupinus mutabilis, and Smallanthus sonchifolius reduced 
the postprandial glycemia and the glucose tolerance during the oral glucose tol-
erance test. Moreover, the in vitro insulin secretion in mice pancreatic islets was 
stimulated only by Amaranthus caudatus, Chenopodium quinoa and Lupinus 
mutabilis. Based on the results of the screening study, we continued evaluating 
the antidiabetic effect of Amaranthus caudatus and Lupinus mutabilis using the 
Goto-kakizaki (GK) type 2 diabetic rats and the respective healthy control the 
Wistar (W) rats. 
The oral administration of A. caudatus and L. mutabilis, separately, improved the 
glucose tolerance and augmented serum insulin levels in both GK and W rats, in 
a dose-dependent way. The daily oral administration of each extract (1000 mg/kg 
b.w.) during 21 days improved the glucose tolerance, increased the serum insulin 
and reduced the glycated hemoglobin. Additionally, the insulin secretion was stimu-
lated in islets isolated from treated animals. Furthermore, both extracts stimulated 
the in vitro insulin secretion in a glucose-independent manner. In perifused islets, 
the insulin secretion was augmented in low glucose (3 mM), increased gradually 
in high glucose (16.7 mM), and was restored to basal levels when each extract 
was removed. The mechanism behind the stimulation of insulin secretion of A. 
caudatus mainly involved the protein kinases A and C activation, while the effect 
was partially dependent on the L-type calcium channel and the G protein-coupled 
exocytosis. L. mutabilis effect depended on L-type calcium channels, PKC and 
PKA systems, G protein-coupled exocytosis and K-ATP channels.  The main con-
stituents found in A. caudatus were amino acids, sugars, and polyphenols, while 
L. mutabilis extract has higher amounts of alkaloids. 
A caudatus is traditionally used to treat disorders in the urinary tract. L. mutabilis, 
on the other hand, is well known for its glycemic lowering effect. Since there is 
a globally increase of antibiotic resistance, we sought to investigate the possible 
role of these two medicinal plants in the treatment of urinary tract infections (UTI). 
We observed that the hydroethanolic extracts from A. caudatus and L.  mutabilis 
prevented the uropathogenic E. coli (UPEC) in vitro infection. A. caudatus 
 inhibited the first steps of infection, adhesion, and invasion of UPEC, including 
ESBL-producing E. coli and other uropathogenic bacteria, including multidrug-
resistant strains. The effect was attributed to the decrease of gene expression of 
uroplakin1a and caveolin-1. L. mutabilis inhibited UPEC adhesion and interfered in 
the adhesion process of other Gram-negative and positive uropathogenic bacteria, 
an effect observed in high glucose concentrations. This effect was explained by a 
downregulation of gene and protein expression of uroplakin-1a and an upregulation 
of the antimicrobial peptide RNase 7. Furthermore, the UPEC biofilm formation 
was inhibited only in low glucose conditions.
 
In summary, this study provides information about the potential use of Amaranthus 
caudatus and Lupinus mutabilis, as a nutraceutical product, since they are part of 
the traditional Bolivian diet. The hydroethanolic extracts of Amaranthus caudatus 
and Lupinus mutabilis have pharmacological properties being promising candidates 
to treat type 2 diabetes mellitus and to prevent urinary tract infections.
  
Keywords: Antidiabetic, antibacterial, urinary tract infections, natural  products, 
nutraceuticals, Amaranthus caudatus, Chenopodium quinoa, Chenopodium 
 pallidicaule, Lupinus mutabilis, Smallanthus sonchifolius, Goto-Kakizaki rats.
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11 INTRODUCTION
1.1 Pathogenesis of type 2 diabetes mellitus 
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by 
elevated glycemia, due to impairment of insulin secretion and/or decreased insulin 
sensitivity [1, 2]. The latter drives to insulin resistance with reduced glucose uptake 
in extra-hepatic tissues and augmented endogenous glucose production by the liver 
[1, 3]. The chronic hyperglycemia [4] and the increased lipolysis together with 
the elevated free fatty acids [5] may lead to further β-cell impairment that affects 
the long-term control of glycemia [6] and reduction of peripheral glucose utiliza-
tion [7, 8]. In the initial stages of the disease, the compensatory insulin secretion 
by the pancreatic β-cells restores plasma glucose levels, but progressively β-cell 
function deteriorates, mainly due to inherited β-cell defect(s) [9]. Long exposure to 
high glucose levels contributes to diabetes-related complications e.g. nephropathy, 
neuropathy, retinopathy and cardiovascular disease [10, 11] (Figure 1). 
Figure 1. Pathogenesis of Type 2 diabetes mellitus. Risk factors involved in the  pathogenesis 
of Type 2 diabetes mellitus and effects on pancreas, liver, adipose tissue and muscle.
21.2 Risk Factors of type 2 diabetes mellitus
T2DM is a result of a complex interaction of polygenetic, epigenetic and lifestyle 
factors [1, 12]. The lifestyle factors include aging, diet, obesity, lack of physical 
activity, stress and factors related to urbanization [13]. The high rate consump-
tion of sugar is related to high risk, as well as a diet rich in saturated fats and 
trans-fatty acids [14]. It has been shown that diet together with physical activity 
reduce T2DM incidence in individuals with impaired fasting blood glucose [15]. 
Interestingly, urbanization can lead to psychological stress factors associated with 
the development of several chronic diseases [16-18]. 
1.3 Epidemiology of type 2 diabetes mellitus
The prevalence of T2DM, according to the World Health Organization (WHO), in 
the adult population by 2010 ranged between 7 and 10% and it is estimated that it 
will be the seventh cause of death by 2030 [19]. T2DM prevalence in developed 
countries is predicted to increase by 20% between 2010 – 2030, while in devel-
oping countries is predicted to increase by 69% [19]. The International Diabetes 
Federation (IDF) predicts that the number of diabetic patients globally will increase 
to 693 million by 2045 [20]. T2DM is considered one of the diseases that causes 
major challenges in the health systems of all countries, regardless of the income 
level and socioeconomic status. In Latin American countries the mortality among 
T2DM patients is two times higher compared to healthy individuals [21].
1.4 Insulin secretion pathway
In the β-cells, insulin is released via two major signaling pathways, the 
 potassium-sensitive ATP (K-ATP) dependent-channel and the K-ATP independent-
channel pathways. In the K-ATP dependent-channel pathway, glucose enters the 
β-cells via the glucose transporter 2 (GLUT-2), where it is phosphorylated to 
glucose-6-phosphate (G6P) by glucokinase enzyme and subsequently metabolized 
via glycolysis and then oxidized by Krebs cycle to generate ATP. 
The ATP leads to an increase in the cytoplasmic adenosine triphosphate/adenosine 
diphosphate (ATP/ADP) ratio that promotes the closure of K-ATP channels,  causing 
membrane depolarization. The membrane depolarization activates the opening 
of L-type voltage-dependent Ca2+ channels (VDCC), which allows the entry of 
free extracellular Ca2+ into the cells. The resulting increase of the  cytoplasmic 
Ca2+  concentration mediates finally the insulin exocytosis [22, 23] (Figure 2).
3Figure 2. Insulin secretion pathway. The potassium-sensitive ATP (K-ATP) dependent-
channel and the K-ATP independent-channel pathways
In the K-ATP independent-channel pathway, glucose-induced insulin  secretion 
can be modulated by other cell signals e.g. by hormones such as glucose-
dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1) and 
 glucagon, which  interact with G-coupled receptors (Gs) that transduce the signal 
by a second  messenger, e.g. cyclic adenosine monophosphate (cAMP), inositol 
1,4,5- trisphosphate (IP3) or diacylglycerol (DAG) [22, 24, 25]. cAMP and DAG 
increase insulin secretion via protein kinase A (PKA) and protein kinase C (PKC) 
pathways, respectively. G-protein Gi is coupled to receptors of inhibitory hormones 
e.g. somatostatin (Figure 2). Besides, the late acting G protein, activated by Ca2+, 
is involved in the exocytosis of insulin granules [22, 26-28].
1.5 Type 2 diabetes mellitus complications
The chronic hyperglycemia leads to microvascular complications in the retina, 
renal glomerulus, and peripheral nerve. Diabetic hyperglycemia in combination 
with dyslipidemia is associated with an accelerated atherosclerotic macrovascular 
disease that affects arteries that supply the heart, brain and lower extremities with 
blood. Hence, diabetic patients have a higher risk of myocardial infarction, stroke 
and limb amputation [12, 29]. Besides, hyperglycemia and insulin resistance might 
4have an impact on the pathogenesis of macrovascular complications due to the 
increase of advanced glycation end product (AGE), polyol pathway, activation of 
PKC isoforms and hexosamine pathway [12, 30].
The polyol pathway converts glucose to fructose by its reduction to sorbitol, which 
is subsequently oxidized to fructose; sorbitol does not cross cell membrane  resulting 
in intracellular osmotic damage. On the other hand, the activation of the polyol 
pathway decreases the concentration of pyrimidine nucleotides NADP+ and NAD+. 
Reduced glutathione (GSH) synthesis requires NADPH, thus a decrease of it would 
induce oxidative stress [30]. AGEs are the covalent union between a reduced sugar 
and a free amino group of proteins, lipids, and nucleic acids. Glycation results in 
altered structure and function of modified biomolecules [30, 31].
Hyperglycemia activates PKC isoforms secondary to ligation to AGE receptors 
and increase of the polyol pathway. Activation of PKC isoforms mediates abnor-
malities in retinal and renal blood flow. PKC activation also induces expression 
of the vascular endothelial growth factor (VEGF) in vascular smooth muscle 
leading to the pathogenesis of neovascularization and endothelial dysfunction in 
diabetes [30, 32]. 
Diabetes-induced glomerular dysfunction such as glomerular hyperfiltration and 
albuminuria is also mediated by PKC activation [33]. The excess of intracel-
lular glucose goes into the hexosamine pathway and increases levels of uridine 
diphospho-N-acetylglucosamine that further modifies proteins to form O-linked 
glycoproteins [30, 34]. Increased O-GlcNAcylation is directly related to hyper-
glycemia-induced toxicity and is related to other processes e.g. redox signaling, 
apoptosis, autophagy, and protein degradation [35, 36]. 
1.6 Urinary tract infections
Diabetic patients have a greater frequency of infections often attributed to 
 hyperglycemia, accompanied with impact on the immune system and neutrophil 
dysfunction interfering with diapedesis and phagocytosis [37]. Especially these 
patients have increased risk of urinary tract infections (UTI) [38]. UTI are most 
common in females, mainly involving the bladder (cystitis, bladder infection), 
but the infection can also ascend and involve the kidneys (acute pyelonephritis, 
kidney infection) [39, 40]. The urinary tract is sterile, except for the external part 
of the urethra, due to urine flow, bladder emptying, and defense mechanisms of 
the epithelia [41].
5Women are about four times more susceptible than men to UTI with enhanced 
risk during the reproductive years [42] and during menopause [43]. Around 50% 
of women experience at least one episode of UTI during their lifetime with recur-
rent episodes within 6 months, even after treatment with appropriate antibiotics 
 [40, 42, 44]. Recurrent UTI is defined as two or more episodes within six months or 
at least three episodes during a year [44]. Therefore, the search for novel approaches 
for the prevention and treatment of UTIs is needed, [45, 46]. 
1.7 Uropathogenic Escherichia coli 
Approximately 90% of all UTIs are caused by uropathogenic Escherichia coli 
(UPEC) [47-49]. UPEC has several virulence factors that play a role in the  infection 
e.g. lipopolysaccharide (LPS), toll/interleukin-1 receptor domain-containing protein 
(TcpC), α-hemolysin, siderophores, adhesive organelles pili or fimbriae type 1, P, 
S, and F1C pili, and capsule [50]. Type 1 fimbriae possess four subunits FimA, 
FimF, FimG and FimH and a short flexible tip composed of minor pilins [51].
1.8 Pathogenesis of urinary tract infections
UTIs result from bacterial transfer from the intestine via the perineum to the 
 urinary tract, where they can colonize and cause infection [52]. The urothelium 
is a transitional epithelium with a basal layer of stem cells, consisting of one or 
more intermediate layers and the superficial layer, with highly differentiated, 
multinucleated superficial facet cells known as umbrella cells. The human  bladder 
urothelium supports frequent changes in volume, thus the umbrella cells have a 
particular composition of lipids and proteins that confers permeability and  regulates 
the passage of water, ions and large macromolecules [44, 53]. The apical mem-
brane has four integral membrane proteins the uroplakins (UPIa, UPIb, UPII, and 
UPIII) that cover the luminal surface of the bladder [54]. 
Urothelial plaques are rich in cholesterol and sphingolipids, molecules that favor a 
microdomain formation, named lipid rafts, structures that lower membrane fluidity 
and permeability. Lipid rafts have also glycolipids and glycosylphosphatidylinositol-
anchored molecules and might contain caveolin-1 proteins, that form a subtype 
of lipid rafts, the caveolae. Lipid rafts are implicated in signal transduction, they 
also possess a versatile endocytic capacity. In vitro binding assays have shown 
that UPEC expressing type 1 pili specifically binds to UPIa and UPIb, located 
in lipid rafts [54-56]. FimH mediates specific recognition of UPIs and bacterial 
adhesion, which is the first step of bacterial infection and may lead to invasion that 
occurs via a cholesterol and dynamin-dependent phagocytosis, process modulated 
by calcium levels, and clathrin adaptor AP-2 that recognize NPXY motifs of the 
cytosolic tail of β1 integrin [57, 58] (Figure 3). 
6Figure 3. Pathogenesis of uropathogenic E. coli infection. The stages of UPEC  infection are 
shown; adhesion, invasion and exfoliation. UPEC adheres to uroepithelium through FimH 
from type 1 pili fimbriae, binding the receptors UPIa. Invasion is  mediated by β1-integrins. 
Internalized bacteria can form IBCs. Once UPEC have attached, AMPs synthesis increases. 
HlyA toxin triggers signals of inflammation,  apoptosis or exfoliation. Filamentous UPEC 
flux out and invade the surrounding  superficial cells. From IBC, motile UPEC efflux and 
are able to invade neighboring cells. UPEC also form biofilms on superficial cells. Motile 
UPEC can ascend to the kidney. 
It was observed that in pyelonephritic strains, the type 1 fimbriae expression 
decreases to allow UPEC ascending to the kidneys, where they attach to digalac-
toside receptors by P fimbriae. FimH can also interact with UPIIIa and stimulate 
signaling pathways for invasion and apoptosis [50, 52]. Invasion mediated by 
FimH interacts with α3 and β1-integrins, clustered with actin and destabilized 
microtubules [52, 54, 57]. The local actin rearrangement results in the internaliza-
tion of bacteria; once internalized, UPEC reside within Rab27b/CD63/Caveolin-
1-positive fusiform vesicles and evades expulsion and phagolysosomal death 
replicating rapidly into the cytoplasm to form biofilm-like complexes both extra 
and intracellularly, the intracellular bacterial communities (IBCs) and located 
deeper in the tissue also forming quiescent intracellular reservoirs (QIRs) which 
serve as transient, protective environments [50, 59, 60].
IBCs formation requires continued type 1 pilus expression after the invasion 
and produces structural components, such as antigen 43, a polysaccharide-rich 
matrix and capsular proteins [59]. Dispersal of UPEC from the IBC is a crucial 
event for bacterial persistence. Inside the IBCs, bacteria are coccoidal, but have a 
 filamentous form when they emerge from the dying cells and may then colonize 
and invade neighboring cells [61]. 
7IBCs are important in UTI pathogenesis and urine sediments from women with 
recurrent UTI have been demonstrated to contain exfoliated bladder epithelial 
cells with IBCs and higher numbers of IBC during acute infection are associated 
with the development of chronic cystitis [44, 59].
During infection, bacterial adhesion stimulates the immune system with the 
 production of antimicrobial peptides and cytokines/chemokines and recruiting 
neutrophils that later may induce tissue damage. Further, the invasion that follows 
the adhesion ends up in apoptosis and exfoliation of bladder cells [39, 53, 62].
1.9 Biofilm
Biofilm is a bacterial consortium structured within a polymer matrix of polysac-
charide, protein and extracellular DNA [61]. The bacterial biofilm is a complex 
structure, which makes it difficult for antibiotics to penetrate, and also makes 
 difficult for the innate and adaptive immune response to reach the bacteria [61, 
63]. The bacterial transition from planktonic to biofilm growth facilitates  bacterial 
survival since, in the matrix, nutrients are trapped for metabolic utilization and 
water is efficiently retained. Bacteria become adapted due to changes in gene 
expression and they can acquire genes for antibiotic resistance from resistant 
clones that could be present inside the biofilm [61, 64, 65]. 
1.10 Immune response in urinary tract infections
The urinary tract is a sterile environment, the urine flow, and micturition rinse 
away nonattached or weakly adherent microbes. The characteristics of urine, low 
pH and osmolarity, salts, urea, and organic acids inhibit bacterial growth [53]. The 
local microbiota normally present in the urogenital tract serve as another origin of 
defense by altering the pH and producing their antimicrobial products, which may 
help controlling infection [43, 66]. Other molecules as soluble and cell-associated 
factors as uromodulin, a renal-specific protein secreted in the urine and secretory 
IgA, act as anti-adherence factors [55, 67]. 
The type 1 fimbriae stimulate cytokine and chemokine synthesis and trigger 
 exfoliation of superficial uroepithelium [62]. Exfoliation of infected bladder 
 epithelium is a host defense mechanism in patients with UTIs. Bladder cell 
 exfoliation is an apoptosis-like mechanism involving DNA fragmentation and 
 caspases activation [68]. Neutrophil recruitment is critical for bacterial  clearance 
and neutrophil accumulation is observed in the urine as pyuria, which is an  indicator 
of UTIs. Bladder epithelial cells induce the expression of ICAM-1 a factor for 
neutrophil migration [67].
8During UTI proinflammatory cytokines like IL-1, IL-6 and IL-8 are increased. 
IL-6 levels relate to the severity of UTI, and together with IL-8, a strong chemoat-
tractant, correlate with the recruitment of neutrophils in urine [50, 62]. Cytokine 
 production in kidney epithelial cell is produced partly due to the interaction 
with P-pili, through a ceramide and serine-threonine kinase-dependent signaling 
 pathway [39, 55]. Toll-like receptor 4 (TLR4), the major LPS sensor in mammals, 
is  present on the luminal surface of the bladder epithelium. CD14, LPS co-receptor, 
is required for TLR4 activation, is present in low levels in healthy kidney; after 
microbial attachment, epithelia liberates endogenous ceramides that trigger TLR4-
dependent responses and IL-8 [49, 50, 62].
The inflammasome NLRP3 plays a role in the progression of UTI. It detects 
extra- and intracellular bacteria, which activate the caspase-1-dependent cell dead 
(pyroptosis), or induce the release of pro-inflammatory cytokines, e.g. IL-1β and 
IL-18 [39, 62]. The inflammasome activation and pyroptosis by UPEC contribute 
to inhibition of intracellular bacterial of replication niches [39].
1.11 Antimicrobial Peptides 
Antimicrobial peptides (AMPs) are oligopeptides found in humans, animals, and 
plants. They are produced by the lymphatic system,  gastrointestinal tract, genitouri-
nary tract, and immune system [69] and confer instant protection against pathogens 
and modulate the immune system [48, 70] against a wide variety of microorganism 
including cancerous cells [71, 72]. AMPs have advantages over conventionally 
used antibiotics, they have broad-spectrum activity with rapid bacterial killing 
and although they have been known for long, only little resistance is known [73]. 
AMPs are positively charged and most of them are amphipathic polycationic 
 peptides, because of their content of lysine and/or arginine amino acids that  primarily 
target the negatively charged bacterial cell membrane. Seconds after the initial 
contact, the disintegration of the lipid bilayer structure is caused [53, 69, 72-74]. 
Additionally, AMPs have immunomodulatory effects including chemotactic 
 attraction, chemokine induction, histamine release, angiogenesis, wound healing, 
or adaptive immunity [71]. In mammals, AMPs modulate the immune system by 
 activation of T cells, activation via Toll-like receptors, increase of  phagocytosis, 
 activation of dendritic cells, and chemoattraction of neutrophils [71, 72]. 
Macrophages, neutrophils and epithelial cells produce AMPs constitutively [71].
91.12 Antimicrobial Peptides in human urinary  
tract infections
Among the human AMPs, defensins and cathelicidins are present in the urinary 
tract [74]. Human β-defensin-1 (HBD-1) is constitutively expressed in bladder 
epithelial cells and highly expressed in the kidney [48, 53]. The luminal surface 
of the tubular epithelia contains higher anti-infective concentrations of HBD1 
[74]. β-defensin-2 (HBD-2) is induced in response to inflammatory stimuli  during 
UTI and has been detected in chronically-infected kidneys [48]. LPS induces 
 transcription of HBD-2 and a slight increase of HBD-1 [75].
Cathelicidin, also called LL-37, is produced in the kidney tubular cells as well as 
urothelial cells [74]. AMPs in healthy urine do not reach microbicidal or inhibitory 
concentrations, an important fact that may prevent the development of resistance 
to the AMPs [76]. LL-37 is constitutively expressed in the urinary tract and after 
bacterial interaction levels of mRNA increase and within minutes, peptide  secretion 
is detected in the surrounding region [77]. LL-37 functions as neutrophils and mast 
cells chemoattractant, prevents apoptosis in neutrophils and keratinocytes, promotes 
angiogenesis, monocyte differentiation, vascular endothelium  proliferation, and 
exhibits anti-inflammatory and anti-endotoxic effects [71]. 
RNase 7 is produced by the bladder urothelium, secreted into urine and produced 
in the intercalated cells of the collecting tubules of the kidney [78]. It induces 
local membrane destabilization due to its affinity for LPS from Gram-negative 
bacteria and peptidoglycan from both Gram-negative and Gram-positive bacteria 
[78]. RNase 7 has broad-spectrum microbicidal activity against many common 
uropathogens [67, 79, 80]. When RNase7 is neutralized in human urine specimens, 
bacterial growth increases [81].
AMPs are active against biofilm-forming bacteria, not only for their  capacity 
to access bacteria in biofilms but they may also prevent biofilm formation. 
While higher concentrations of LL-37 are needed to kill bacteria, subinhibitory 
 concentration can prevent the formation of new biofilm [82]. KT2 and RT2  modified 
AMPs, the semi-synthetic peptide SB056, peptide 1018 and others have been 
constructed and shown to be active against both planktonic and biofilm-forming 
bacteria [73]. On the contrary, different mechanisms of AMP resistance by biofilm 
producing bacteria have been described due differences in motility or metabolism 
of the bacterial subpopulations [73, 83]. 
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1.13 Diabetes and urinary tract infections
The prevalence and severity of UTI increase in diabetic patients [37, 84] since 
they are prone to UTI-related complications due to conformational and molecular 
changes in bladder epithelium and disruption of the host immune response  [85-87]. 
Predisposition to UTIs in T2DM results from factors as glycosuria; increase 
 bacterial adherence and immune dysfunction. T2DM patients treated with the 
sodium-glucose cotransporter-2 (SGLT2) inhibitors tend to develop UTI by the 
induced glycosuria [86].
Bacterial adhesion, mediated by UPEC type 1 fimbriae, in diabetic patients is 
increased due to changes in the carbohydrate moieties in the glycoproteins of the 
luminal urothelial surface [85, 88]. During diabetes progression, the  accumulation 
of AGEs, enhances bacterial adhesion, which has been proved by in vitro  binding 
of type 1 fimbriae to several AGE products and further confirmed in diabetic mice 
where treatment with AGE inhibitor pyridoxamine reduces bacterial  adhesion 
[85, 88].
1.14 Current therapy of type 2 diabetes mellitus
The antidiabetic therapy goal is to achieve optimal glycemic control, and thereby 
to prevent or delay the progression of complications [89]. Ideally, the antidiabetic 
therapy should also help the patient to avoid episodes of pronounced hyper or 
hypoglycemia.  Current antidiabetic medication includes biguanides, sulfony-
lureas, meglitinides, thiazolidinediones (TZD), dipeptidyl peptidase 4 (DPP-4) 
inhibitors, GLP-1 analogs (also called incretins), sodium-glucose cotransporter 
(SGLT2) inhibitors, and α-glucosidase inhibitors [89, 90].
The sulfonylureas increase insulin secretion by blocking the K-ATP channels 
in pancreatic β cells. The first-generation sulfonylureas (e.g. chlorpropamide, 
tolazamide, and tolbutamide) have a long half-life, higher risk of hypoglycemia, 
and slower onset of action, as compared to the second-generation (e.g. glipizide, 
glimepiride, and glibenclamide) [91, 92]. 
Meglitinides e.g. repaglinide and nateglinide, are non-sulfonylurea secretagogues, 
that bind to the sulfonylurea receptor in β-cells, however weaker than sulfonylurea, 
leading to a short-acting insulin-releasing effect [93].
Metformin is a biguanide that activates the adenosine monophosphate-activated 
protein kinase (AMPK) in the liver to induce hepatic glucose uptake and to inhibit 
gluconeogenesis. Besides, the substance has a weak effect on glucose uptake in 
skeletal muscle by AMPK activation. Metformin confers a low risk of hypogly-
cemia and low probabilities of weight gain [94]. 
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The incretins exert antidiabetic effects by several mechanisms, i.e. stimulation 
of the glucose-dependent insulin secretion, suppression of glucagon secretion, 
 slowing down the gastric emptying, and reduction of appetite, thereby also inducing 
weight loss. In T2DM patients, the incretin effect of the main endogenous  incretin, 
 glucagon-like peptide (GLP-1) is usually reduced [95]. The incretin mimetics 
include two types of drugs, GLP-1 receptor agonists and DPP-4 inhibitors. Current 
GLP-1 receptor agonists are e.g. exenatide and liraglutide. Dipeptidyl peptidase 
4 (DPP-4) inhibitors include sitagliptin, saxagliptin, vildagliptin, linagliptin, and 
alogliptin [96]. Their mode of action is to increase the endogenous GLP-1 by 
inhibiting the degradation of the hormone by the DPP-4 enzyme [90, 97].
The sodium-glucose co-transporter inhibitors (SGLT2 inhibitors) lower blood 
glucose levels by blocking glucose reabsorption from the primary urine in the 
proximal renal tubule. Available SGLT2 inhibitors are canagliflozin,  dapagliflozin, 
and empagliflozin. These drugs have also been shown to reduce the risk of 
 cardiovascular diseases [90, 97, 98].
Rosiglitazone and pioglitazone are thiazolidinedione (TZD) agents and  agonists 
of the peroxisome proliferator-activated receptor-gamma (PPARγ). TZDs 
 facilitate  glucose uptake in adipose tissue, muscle, and liver; reduce free fatty 
acid  accumulation and inflammatory cytokines; augment adiponectin, and preserve 
β-cell integrity and function [89, 90, 97].
The alpha-glucosidase inhibitors compete and reversibly inhibit the intestinal alpha-
glucosidases. Acarbose prolongs the carbohydrate digestion time thus, reduces the 
rate of glucose absorption [99].
Insulin is often applied subcutaneously when monotherapy or a combination of oral 
antidiabetic drugs fail. Rapid-acting insulin analogs (lispro, aspart, or  glulisine) 
are used before meals, often in combination with long-acting, basal insulin (NPH, 
detemir, glargine, or degludec) once or twice daily [100]. To control the peripran-
dial glucose premixed (biphasic) insulin analogs (70/30 aspart mix, 75/25 or 50/50 
lispro mix) can be administrated two or three times [101, 102].
1.15 Current therapy against urinary tract infections
Treatment guidelines for uncomplicated UTI recommend the use of nitrofuran-
toin and pivmecillinam as first choice, while trimethoprim and cefadroxil are the 
 second choices [43, 103, 104]. In specific cases, antibiotic prophylaxis can be used 
 during a prolonged, but limited period [48]. However, the increase in antimicrobial 
resistance makes treatment strategies more complex [105]. 
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The high frequency of extended-spectrum β-lactamases (ESBL) E. coli or K. 
pneumoniae, which inactivate β- lactam antibiotics such as cephalosporins [106] 
has extended the use of carbapenems. Carbapenem resistance, ESBLCARBA, is the 
result of the production of carbapenemases, e.g. K. pneumoniae carbapenemase 
(KPC-type), New Delhi Metallo-β- lactamase (NDM-type) and OXA-48-type 
enzymes. Unfortunately, worldwide consumption of carbapenems, especially in 
developing countries, increased the carbapenem resistance.
The acquisition of ESBL or carbapenemase genes is mediated by the transference 
of resistance gene carried in plasmid, resulting in the development of multidrug-
resistant strains (MDR); strains that are resistant to 3 groups of antibiotics [106, 107].
1.16 Medicinal plants in the treatment of type 2 diabetes 
mellitus
Natural products are believed to be safe and some T2DM patients use them to 
avoid the progression of the disease or its complications [108, 109]. More than 
1200 plant species and many natural products, vitamins, and minerals are reported 
to be used as complementary or supplement treatment in T2DM [110, 111]. 
Momordica charantia, aerial parts and seeds, have insulin mimetic and insulin 
secretagogue activity in animal models and in clinical trials [109]. Cinnamomum 
verum (cinnamon) reduces the fasting plasma glucose, low-density lipoprotein-C, 
triglycerides, and total cholesterol [112, 113]. Morus alba reduces postprandial 
blood glucose in women with impaired glucose tolerance [114]. Zingiber officinale 
Roscoe (ginger) enhances the insulin secretion and glucose uptake of in skeletal 
muscles [115]. Ginger as a dietary supplement reduces the glycated hemoglobin 
(HbA1c) [113, 116]. Gymnema sylvestre regenerates pancreatic islet and  inhibits the 
glucose absorption from the intestine [115]. Gynostemma penthaphyllum  contains 
substances that increase insulin sensitivity [117] and insulin secretion [118, 119] 
and also suppresses the hepatic glucose output [120]. 
Among the phytochemical compounds reported to have antidiabetic properties, 
we can mention terpenoids, flavonoids, anthocyanins, and alkaloids. Triterpenoids 
improve glucose uptake and insulin secretion. The flavonoid naringenin reduces 
the intestinal glucose absorption, reduces the renal glucose reabsorption, and 
increases glucose uptake in muscle and fat tissues. Kaempferol has an antioxidant 
effect that reduces the oxidative stress and preserves the pancreatic β-cell mass 
[121]. Anthocyanins from blueberries improve regulation of the glucose uptake 
in skeletal muscle, decrease the glucose production in the liver and protect the 
β-cells function due to their antioxidant properties [122]. Alkaloids e.g. berberine, 
lupanine neferin, and piperine improve the insulin-signaling pathway cascades in 
β cells, myocytes, adipocytes, and hepatocytes [121].
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1.17 Medicinal plants in The treatment of urinary tract 
infections
The traditional medicine in different countries use different plant preparation to 
treat UTI, some of them have scientific evidence that supports their use [111, 123]. 
Some plant extracts exhibit direct antibacterial effect against uropathogenic  bacteria 
[124, 125], others interfere with bacterial adhesion by interaction with bacterial 
outer membrane proteins as reported for rhizome of Agropyron repens L. and the 
stigmata of Zea mays L. [126]. Cranberry components interfere with bacterial 
adhesion by direct interaction with P-fimbriae of UPEC [127, 128]. However, in 
a clinical study, patients with recurrent UTI were either given 12 months prophy-
laxes with cranberries or trimethoprim-sulfamethoxazole. In spite of the in vitro 
results, patients on cranberry prophylaxes had more recurrences, which occurred 
earlier than those on trimethoprim-sulfamethoxazole [129]. 
The combination of plant extracts plus D-mannose, a prophylactic agent that 
 inhibits bacterial adherence binding and blocking FimH adhesin [130], prevents 
the recurrence of UTIs. Patients treated with berberine, arbutin, birch, and forskolin 
and D-mannose had a lower incidence of cystitis [131]. 
Furthermore, extracts from medicinal plants have also demonstrated an effect 
on the host cell, inhibiting in vitro UPEC adhesion as reported for Orthosiphon 
 stamineus and Urtica spp. [126]; and Luteolin-glycosides and related flavons from 
Apium graveolens fruits [132]. In previous studies we have shown that Clinopodium 
bolivianum in vitro decreases UPIa expression, resulting in lower adhesion and 
invasion of UPEC and up-regulates caveolin-1. In uninfected cells, however, IL-8 
decreased compared to non-treated uroepthelial cells. Moreover, Clinopodium 
bolivianum reduces UPEC biofilm formation [133]. Citrus reticulata decreased 
β1-integrin expression and reduced bacterial invasion [134].
Inhibitory effect of biofilm has been reported by R. officinalis and Origanum  majorana 
oil [124] and extracts from Herniaria glabra and Vaccinium vitisidaea [135].
1.18 Nutraceuticals source of Novel Therapies
Natural products are a potential source of novel therapies; most of them are safe 
and are an attractive complement to the regular therapies [111, 115]. Among natural 
products a nutraceutical is “a food or part of a food that provides health benefits 
in addition to its nutritional content” [136, 137]. Nutraceuticals are well accepted 
in human consumption, being food with pharmaceutical effect. However, in most 
cases, evidence of the pharmacological properties is moderately explained or 
absent [138, 139]. Thus, it would be important to understand the mechanisms of 
action of active substances contained in nutraceuticals that may improve health 
or prevent pathologies [140].
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Different natural products with antidiabetic and/or antibacterial properties have 
been reported to improve glycemic control and prevent long-term complications 
[141, 142]. Interestingly, Bolivia has huge biodiversity that could be a potential 
source of new treatment drugs. Thus, the alternative approach proposed by this 
study is to evaluate the antidiabetic and antibacterial promising plants, which will 
be a source of potential nutraceutical products [111, 143, 144].
1.19 Plants under study
Based on their traditional use, we have selected five Bolivian food plants with 
potential nutraceutical effects; the following information highlights Andean plants 
that are currently part of the Bolivian nutrition schemes [111, 144]. 
Amaranthus caudatus (A. caudatus), common name kiwicha, is a pseudocereal, its 
seeds are usually consumed in beverages, food preparations e.g. soup, bread or as 
toasted flour. Traditional medicinal properties attributed to A. caudatus are blood 
purifier, diuretic, and digestive [145-148]. Among its pharmacological properties, 
it showed anti-hyperglycemic activity, and studies using water decoction extract 
reported α-amylase inhibitory activity [149]. In addition, the methanolic extract 
of A. caudatus leaves reduced glycemia and lipid profile of streptozotocin (STZ)-
injected rats, a model of type I diabetes [147] (Figure 4). 
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Figure 4. Pseudocereal plants under study. Photographs of plants and seeds of Amaranthus 
caudatus (A-B) Chenopodium quinoa Willd (C-D), Chenopodium  pallidicaule (E-F), 
respectively.
Chenopodium quinoa Willd (C. quinoa), common name quinua, is a  pseudo-cereal 
that has a balance between oil, protein, and fat and it is considered as a nutraceutical 
that may lower the risk of various diseases due to its content of minerals, vitamins, 
and antioxidants [148]. C. quinoa seeds are also used in food  preparations as part 
of the diet of rural Bolivian families, including a variety of soups and refresh-
ments [150]. Phenolic compounds responsible for the antioxidant activity and 
anti-radical, reducing power, represent the nutraceutical potential of C. quinoa 
[151-153] (Figure 4).
Chenopodium pallidicaule (C. pallidicaule), common name kañiwa, is a pseudo-
cereal, its seeds are usually consumed in refreshments [153]. C. pallidicaule anti-
oxidant properties and composition are similar to that of C. quinoa and A. caudatus 
[154-156]. C. pallidicaule contains a variety of functional molecules; flavonol 
glycoside, quercetin, isorhamnetin, and kaempferol, components  identified in its 
raw whole seed flour. Their quercetin derivatives were correlated with their high 
radical scavenging-linked anti-oxidant activity [157, 158] (Figure 4).
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Lupinus mutabilis (L. mutabilis), common name tarwi, is a legume that contains 
proteins rich in the essential amino acid lysine [159] (Figure 5). Its seeds contain 
high amounts of alkaloids, molecules responsible for its bitter taste [160]. Ethanolic 
extract of L. mutabilis showed hypoglycemic activity in normoglycemic rats with 
49% of reduction of glycemia. Furthermore, a clinical trial showed that L. mutabilis 
consumption in normal healthy young individuals did not change importantly the 
glycemia and insulin, but, similar doses significantly reduce glycemia in hyper-
glycemic individuals [161].
Figure 5. Edible bean and tuberous root under study. Photographs of Lupinus mutabi-
lis, plants and seeds (A-B) and Smallanthus sonchifolius, plant and tuberous roots (C-D)
Smallanthus sonchifolius (S. sonchifolius), common name yacon is a tuberous root 
consumed in rural valley regions where it is well known for its property to induce 
weight loss [162]. Its content of inulin and fructo-oligosacharides, components that 
cannot be digested, makes it a hypocaloric food ideal for consumption in  diabetic 
patients [163]. Daily administration of organic extracts from S.  sonchifolius leaves 
for 8 weeks increases the plasma insulin levels [164]. The water extract of its leaves 
reduced glycemia, as well as body weight in type I diabetic STZ rats [165] and 
its decoction significantly decreases glycemia in STZ-diabetic rats by the inhibi-
tion of the α-glucosidase [166]. S. sonchifolius roots flour as a diet supplement 
increases the glutathione peroxidase and glutathione levels in the liver and kidney 
in diabetic rats [167] (figure 5).
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2 AIMS
The overall objective of this thesis was to evaluate the potential antidiabetic and 
antibacterial effect of selected Bolivian nutraceutical plants, traditionally used to 
prevent such diseases.
Specific aims were:
1. To screen the glycemia-reducing effect of aqueous, ethanolic and hydroetha-
nolic extracts from five Bolivian nutraceutical plants e.g. Amaranthus  caudatus, 
Chenopodium quinoa, Chenopodium pallidicaule, Lupinus mutabilis and 
Smallanthus sonchifolius using healthy Swiss albino mice. 
2. To evaluate the putative antidiabetic effect and the mechanism of action of 
Amaranthus caudatus and Lupinus mutabilis in the type 2 diabetic model the 
Goto-Kakizaki rats and the healthy control, Wistar rats.
3. To evaluate the antibacterial effect of Amaranthus caudatus and Lupinus 
 mutabilis using in vitro infection with uropathogenic E. coli and other uropatho-
genic bacterial strains in uroepithelial cells. 
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3 MATERIAL AND METHODS
3.1 Experimental design 
The present study explored the antidiabetic and antibacterial properties of Bolivian 
plants under the following experimental approach (Figure 6).
Plant Extracts
Active extracts
Glycemia-reducing 
Screening 
(Swiss albino mice)
Amaranthus caudatus
Lupinus mutabilis 
Phytochemical
characterization
Antidiabetic studies
(GK rats)
In vitro Antidiabetic 
studies (pancreatic islets)
Inhibition of 
bacterial adhesion
and invasion
Antibacterial Studies
(UPEC infection in uroepithelial cells)
Mechanism of insulin
secretion studies
(pancreatic islets)
Antimicrobial
Peptides
modulation
Bactericidal effect
Biofilm inhibition
Figure 6. Experimental design followed in antidiabetic and antibacterial studies.
3.2 Plant extracts and phytochemical analysis 
The plant specimens were collected from local producers to have locally produced 
material avoiding possible contamination with other plant species or possible 
contamination during storage and selling. Location was recorded to have that 
 reference for further collections. All plant species were prepared for authentication 
to verify the correct taxonomy assignation by the Herbario Nacional de Bolivia 
[168] (Table 1) (Paper I, II, III, IV and V).
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Table 1. Information of collection places of plants under study 
Scientific name Location Coordinates
Amaranthus caudatus
(A. caudatus)
Tomina, Tomina Province, Chuquisaca 19°25´53.96´´S 
64°15´5.44´´W
Lupinus mutabilis
(L. mutabilis)
Ancoraimes, Omasuyos Province, La Paz 15°55´19.3´´S 
68°53´50.1´´W
Chenopodium quinoa
(C. quinoa)
Huancane, Los Andes Province, La Paz 16°18´14.14´´S   
68°32´35.88´´W
Chenopodium pallidicaule
(C. pallidicaule) 
Peñas, Los Andes Province, La Paz 16°13´55.02´´S 
68°29´41.70´´W
Smallanthus sonchifolius
(S. sonchifolius)
Sorata, Laracaja Province, La Paz 15°45´12.18´´S 
68°39´19.46´´W
Plant extracts were prepared using different solvents, distilled water (aqueous 
extract, Aq), 70% ethanol solution in distilled water (hydroethanolic extract, 
EtOH70) and absolute ethanol (ethanolic extract, EtOH). Solvents were removed 
using a rotary evaporator and a freeze drier [133, 169] (Paper I, II, III, IV and V).
Initially, the hydroethanolic extracts were characterized using standard phyto-
chemical qualitative tests [170] (Paper I). In further studies, active hydroetha-
nolic extracts were analyzed by High Performance Liquid Chromatography-High 
Resolution Mass Spectrometry Analysis (HPLC-HRMS) followed by Nuclear 
Magnetic Resonance analysis (NMR) for A. caudatus and Gas Chromatography-
Mass Spectrometry Analysis (GC-MS) for L. mutabilis. Chemical standards were 
used to assign tentative identification [133] (Paper II, III, IV and V). 
3.3 Antidiabetic Studies 
3.3.1 Swiss albino mice
Swiss Albino mice were used in screening for glycemia-reducing effect and in 
acute toxicity studies. This mouse is an outbred strain, with some variability 
between animals. Despite its variability, following the standard protocols [171], 
the parameters we measured, hematological, blood biochemical parameters and 
behavior were enough reproducible. Animals were provided by the animal facility 
of the Facultad de Ciencias Farmacéuticas y Bioquímicas, Universidad Mayor de 
San Andrés (Paper I).
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3.3.2 Goto-Kakizaki rat model
The Goto-Kakizaki rat (GK rat), a non-obese model of T2DM, was used in 
 antidiabetic studies. This model was originated by repeated inbreeding of Wistar 
(W) rats with impaired glucose tolerance and is characterized by impaired β-cell 
mass and function and glucose intolerance [9]. Constant features of GK rat are 
glucose intolerance, mainly due to impaired glucose-induced insulin secretion. 
In GK rat islets, the GLUT2 is under-expressed but the islet glycolytic rates are 
normal or increased. One major defect in GK rats is the reduced islet expression 
of the  exocytotic soluble SNARE receptor proteins involved in the docking and 
fusion of insulin granules [172]. Additionally, PKC isoenzymes in GK rat islets 
are diminished and/or have abnormal activation [9]. GK rats used came from the 
Stockholm colony bred in the animal facilities of the Department of Molecular 
Medicine and Surgery, of the Karolinska Institutet [173, 174]. W rats, used as 
healthy control animals were purchased from Charles River, a commercial breeder. 
3.3.3 Ethical considerations
Glycemia reducing screening studies, performed in Bolivia, were approved by the 
Ethics committee from the Universidad Mayor de San Andrés; approval CEI-UMSA 
0115 (Paper I). Anti-diabetic studies, performed in Sweden, were approved by 
the Laboratory Animal Ethics Committee of the Karolinska Institutet; approval 
Dnr. N50/2014 (Papers II and III).
3.3.4 Screening for glycemia-reducing effects
The effect of plant extracts on glycemia was evaluated in non-fasted mice by single 
oral administration. Extract doses tested were: A. caudatus, L. mutabilis, C. quinoa, 
and C. palidicaule, ethanolic extract (4000 and 2000 mg/kg b.w.), hydroethanolic 
and aqueous extracts (2000, 1000 and 500 mg/kg b.w). S. sonchifolius, ethanolic 
and aqueous extracts (1000 mg/kg b.w.), and hydroethanolic extract (1000, 500 
and 250 mg/kg b.w). For experimentation, aqueous and hydroethanolic extracts 
were dissolved in distilled water, and ethanolic extracts were dissolved in 1.5% 
water solution of Tween 20. The placebo groups received distilled water and 1.5 % 
water solution of Tween 20. Blood samples from the tip of the tail were collected 
1, 2, 4 and 6 h, after administration of the extracts [175]. Glycemia was measured 
using a glucometer (Paper I).
3.3.5  Oral Glucose Tolerance Test
The oral glucose tolerance test (OGTT) was used to evaluate the clearance of 
an oral glucose load in fasted animals; in parallel, the glucose-dependent insulin 
secretion can be followed [176, 177]. Extracts were orally administrated, one hour 
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before the test. After the glucose challenge, (3 g/kg b.w.) for Swiss mice and W 
rats, while (2 g/kg b.w.) for GK rats, blood samples were collected in intervals of 
time to follow the glucose clearance (0, 15, 30, 60, and 120 min). Blood samples 
were collected after cutting tip of the tail, to get enough sample to detect glycemia 
by using a glucometer [118, 173, 174]. Serum insulin was also measured at time 0 
and 30 min, determined by radioimmunoassay (RIA) [178]. The improvement in 
glucose tolerance was analyzed at each time point compared with placebo  controls 
and also by calculating the area under the glucose clearance curves (AUCs) [179] 
(Papers I, II and III).
3.3.6  Long-term Treatment Evaluation
The effects of A. caudatus and L. mutabilis were evaluated in long-term oral 
 treatment of GK and W rats during 21 days, according to the following scheme 
(Figure 7) (Papers II and III): 
Figure 7. Experimental approach followed in long-term experiments. Treatment  during 
21 days group 1: GK rats treated with A. caudatus or L. mutabilis (1000 mg/kg b.w.); group 
2: GK rats, placebo vehicle; group 3: W rats treated with A. caudatus or L. mutabilis (1000 
mg/kg b.w.); group 4: W rats, placebo vehicle. Time intervals for sampling collection are 
indicated to conduct the OGTT, non-fasting glucose (NFG),  glycated hemoglobin (Hb1Ac), 
and islets collection at the endpoint of treatment.
3.3.7 Sub-acute toxicity studies
The sub-acute toxicity of extracts was evaluated in W rats. Dry extracts were 
incorporated to regular chow food in quantities to reach a daily dose of 1000  mg/
kg b.w. of A. caudatus or L. mutabilis.  Treatment was conducted for 28 days, 
following changes in behavior and weight; at the end point blood sample was 
collected to determine hematological and biochemical parameters, according to 
guideline 407 of the Organization for Economic Cooperation and Development 
[180] (Papers II and III).
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3.3.8 Pancreatic Islets Isolation 
To explore the effect of A. caudatus and L. mutabilis on β-cell function, we meas-
ured the insulin release in isolated pancreatic islets. To digest the pancreas in the 
isolation procedure we used collagenase type I dissolved in HBSS 9   mg/10 ml 
for Swiss mice (Paper I) and Wistar rats (Papers II and III), and 24 mg/10 ml 
for GK rats (Papers II and III), followed by a gradient density isolation of islets 
using a mixture of Histopaque 1077 and 1119, ratio 2:1. The free islets were 
hand-picked using a stereomicroscope and were then stabilized by culturing them 
overnight in RPMI supplemented with 30 mg of L-glutamine, antibiotics (100  UI/
ml penicillin and 0.1 mg/ml streptomycin) and 10% of heat-inactivated fetal calf 
serum [174, 181]. 
3.3.9 Insulin Release
Overnight-cultured round shape and well-defined islets were collected in batches 
of 3 islets per condition. After a preincubation during 30 min in KRB (Krebs-
Ringer bicarbonate) buffer, pH 7.4 at 37°C in 3.3 mM glucose, the islet batches 
were incubated in KRB-buffer in low glucose condition (3.3 mM glucose) to 
measure the basal insulin and in high glucose conditions (16.7 mM glucose) to 
measure the glucose-stimulated insulin release. A set of those conditions was tested 
in  presence of A. caudatus (5 – 50 mg/ml) or L. mutabilis (5–20 mg/ml) extracts. 
Insulin release was evaluated during 60 min at 37°C in a shaking water bath [174, 
182]. Aliquots of the incubation buffer were collected for insulin determination 
by RIA (Papers II and III) [178].
3.3.10 Islet Perifusion
To explore the effect of A. caudatus (20 mg/ml) and L. mutabilis (10 mg/ml) 
extracts on the kinetics of insulin release, batches of 40 or 50 islets were layered in 
a perifusion chamber between polystyrene beads where KRB buffer was perifused. 
The basal insulin secretion was established during the first 20 min (KRB 3.3 mM 
glucose), then buffer was replaced to KRB 3.3 mM glucose plus extracts period 
0 - 14 min; then to KRB 16.7 mM glucose plus extracts period 16 - 30 min; finally 
to KRB 3.3 mM glucose without extracts, during 20 min [182]. The AUCs for 
insulin release were calculated for treatment periods in presence of extracts, sub-
tracting the basal value at the beginning of treatment (Papers II and III).
3.3.11 Cytotoxicity in isolated Pancreatic Islets
To evaluate the possible toxic effect of tested concentrations of A. caudatus and L. 
mutabilis extracts, that could be responsible for the presence of insulin in buffer 
due to islet membrane destabilization and insulin leakage, islets were incubated 
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in presence of extracts A. caudatus (5 – 50 mg/ml) or L. mutabilis (5–20 mg/ml) 
in medium RPMI supplemented with 30 mg of L-glutamine, antibiotics (100 UI/
ml penicillin and 0.1 mg/ml streptomycin) and 10% of heat-inactivated fetal calf 
serum for 1 to 24 h at 37 °C. The cell viability was determined by the reduction 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) salt to 
a water-insoluble purple product formazan that was further solubilized using a 
solution of 0.05 M of HCl in isopropanol and OD was measured at 595 nm [183-
186] (Papers I, II and III).
3.3.12 Mechanisms of Insulin Secretion 
The mechanism of insulin secretion was evaluated using different inhibitors of key 
players in the glucose-dependent insulin secretion pathway. Islets were incubated 
in the presence of each inhibitor together with A. caudatus or L. mutabilis extracts. 
Conditions where the extract effect is inhibited means that this process is likely to 
be involved in the extract effect on insulin secretion. The inhibitors we used were: 
0.25mM of Diazoxide (Dx), an opener of ATP-dependent K+ channels, active in 
the presence of Mg2+ [187, 188]; Dx plus 50 mM of KCl, to depolarize the β-cells 
[179, 189]; 10 μM of Nifedipine (Nf), a blocker of L-type Ca2+ channels [182, 187, 
190]; 10 μM of N-[2-bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide 
(H-89 dihydrochloride hydrate), a cell-permeable inhibitor of cAMP-dependent 
PKA, that binds to the ATP-binding site of the catalytic subunit, independent of 
magnesium [179, 191, 192]; 1.5 μM of calphostin C (Cal-C), a perylene quinone 
PKC inhibitor derived from the fungus Cladosporium cladosporoides, that targets 
the PKC regulatory domain [179, 189, 192, 193]; and 100 ng/ml of Pertussis toxin 
(Ptx), produced by Bordetella pertussis, an inhibitor of exocytic G proteins by 
ADP ribosylation of GTP-binding [26]. 
Following procedure previously described for insulin release, islets were incubated 
in presence of A. caudatus (20mg/ml) or L. mutabilis (10 mg/ml) hydroetha-
nolic extracts in presence or absence of each inhibitor (Dx, Nf, H89 and Cal-C) 
for 60 min at 37°C. For PTx, islets were incubated with PTx in RPMI medium 
overnight, then islets were collected for insulin release assay in presence of each 
extract (Papers II and III) [174].
3.3.13 Glucose Uptake Evaluation
We explored the possible effect of A. caudatus and L. mutabilis extracts on insulin 
sensitivity in primary adipocytes isolated from epididymal fat from GK and W rats. 
We used a digestion protocol with type II collagenase. Isolated adipocytes were 
incubated with [3-3H]-glucose (1 μCi/mL) for 2 h at 37°C and d-glucose solution 
in presence or absence of extracts and the radioactivity of 3H-glucose incorporated 
in the de novo synthesized lipids was measured [194] (Papers II and III). 
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3.4 Antibacterial Studies 
3.4.1 Bacterial strains
Uropathogenic E. coli No.12 obtained from a child with acute pyelonephritis and 
equipped with type 1 and P-fimbriae as well as curli and cellulose [133], and the 
ESBL producing E. coli (CCUG55971) resistant to beta-lactam antibiotics, like 
most cephalosporins [195] and Escherichia coli (ATCC 25922), a control strain 
for antimicrobial susceptibility [196], were used to evaluate the effect of herbal 
extracts during infection (Paper IV). 
The impact of extracts on biofilm formation was studied. To promote expression 
of fimbriae, strains were cultured in Luria Bertani broth and agar plates without 
salt, for at least 24 h at 37°C prior to infection (Paper V) [133].
In addition, the effects of the herbal extracts were evaluated using other  uropathogenic 
Gram-negative Klebsiella pneumoniae (ATCC 13883), _multidrug-resistant 
(MDR) Klebsiella pneumoniae (CCUG 58547), Proteus mirabilis (ATCC 29245), 
Pseudomonas aeruginosa (ATCC 27853); and Gram-positive Enterococcus faecalis 
(ATCC 29212), Staphylococcus saprophyticus (ATCC 15305), and Streptococcus 
agalactiae (ATCC 13813) [60] (Papers IV and V).
3.4.2 Cell lines
Human bladder epithelial cell lines, T24 (HTB-4; ATCC) isolated from transitional 
cell carcinoma and 5637 (HTB-9; ATCC) isolated from grade II carcinoma were 
used as host cells for in vitro infection. T24 cells were cultured in McCoy’s 5A 
medium while 5637 cells were cultured in RPMI 1640 with L-glutamine medium, 
both supplemented with 10% of fetal bovine serum (FBS) and were maintained 
at 37°C and 5% CO2 [133, 134] (Papers IV and V). 
3.4.3 Cell Viability Assay
Cell viability assay was determined by the colorimetric XTT reduction assay. This 
assay is based on the reduction of the tetrazolium salt XTT (2,3-bis (2-methoxy-
4-nitro-5-sulphophenyl)-5-carboxanilide-2H-tetrazolium, monosodium salt) to a 
water-soluble product formazan (orange-colored), produced by the mitochondrial 
dehydrogenase in metabolically active cells. The direct relationship between the 
intensity of the formazan and the number of viable cells is measured [134, 185]. 
T24 cells were cultured in McCoy’s culture medium in presence of A. caudatus 
(2.5 – 20 mg/ml) during 24 h (Paper IV); while T24 and 5637 cells, cultured in 
McCoy’s5A or RPMI 1640 medium, were treated with L. mutabilis (0.3 – 20 mg/
ml) during 24 h and with L. mutabilis (1 mg/ml) during 48 and 72 h (Paper V). 
Viability was calculated referred to control cells cultured in absence of extracts.
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3.4.4 Antibacterial effect
The direct antibacterial effect of A. caudatus and L. mutabilis was tested using 
the minimum inhibitory concentration (MIC) that is defined as the lowest con-
centration of an antimicrobial agent that inhibits the visible growth of a micro-
organism after overnight incubation [133, 197]. Extracts were serially diluted in 
Mueller Hinton broth (MHB), tested concentration for A. caudatus were 250 to 
1.95 mg/ml and for L. mutabilis 50 to 0.2 mg/ml; the final inoculum of bacteria 
was 5×105CFU/ml. Bacteria cultured only with MHB was the negative control 
[133] (Papers IV and V).
3.4.5 Cell infection assay
T24 cells were seeded in a density of 2x105 cell/well in a 24 well plate and were 
incubated overnight. For treatment with A. caudatus (10 mg/ml) or L. mutabilis 
(1 mg/ml) hydroethanolic extracts, during 24 h before infection, extracts were 
dissolved in the respective medium in normoglycemic glucose conditions (5mM) 
(Paper V) or hyperglycemic (11 mM) conditions (Paper IV and V). Cells were 
infected with 106 CFU/ml of E. coli No. 12 or E. coli ESBL-producing strain 
for 30 minutes in 37°C and 5% CO2. Control cells were cultured in presence of 
medium only [133, 134, 198]. 
3.4.6 Adhesion and invasion assay
The effect of A. caudatus and L. mutabilis on the initial steps of E. coli infection 
was investigated. In adhesion assay, T24 cells, pretreated during 24 h with A. 
caudatus (10 mg/ml) or L. mutabilis (1 mg/ml) and infected as described before 
were washed with PBS to remove the non-adherent bacteria. Remaining adher-
ent bacteria were detected after cells were lysed (0.1% triton-X-100 in PBS) and 
bacteria present in the lysate were cultured on blood agar and were quantified after 
overnight culture of serial dilution [133, 134] (Papers IV and V).
Invasion assay measured the number of bacteria able to invade uroepithelial cells. 
Bacteria were allowed to adhere to the T24 cells, pretreated with A. caudatus (10 mg/
ml) or L. mutabilis (1 mg/ml) as in the adhesion assay, and the  non-  adherent bac-
teria were washed away with PBS and replaced with fresh medium for 1 h. After 
allowing invasion, cells were treated with gentamycin for 30 min to kill remaining 
extracellular bacteria, while intracellular bacteria were not affected. Finally, the 
number of invading bacteria was calculated lysing the cells (0.1% triton-X-100 
in PBS), and the number of intracellular bacteria was referred to the number of 
adhered bacteria [133, 134]. 
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Additionally, the effect on adhesion and invasion of other bacteria strains, 
 responsible for the development of UTI were evaluated. Extracts were dissolved 
in supplemented medium with normoglycemic glucose conditions (5mM) (Paper 
V) and hyperglycemic (11 mM) conditions (Papers IV and V), both extracts were 
present throughout the entire experiment. 
3.4.7 Gene expression of adherence and invasion molecules
To explore the modulation of adhesion molecules that allow bacteria adherence 
and invasion to host uroepithelial cells, we evaluated the gene expression of UPIa 
in T24 treated cells for 24 h; and gene expression of caveolin-1 and β1-integrin 
evaluated in T24 treated cells for 24 h followed by infection with E. coli No. 12 or 
E. coli ESBL-producing strains during 30 min. A. caudatus (10 mg/ml) treatment 
was done in 11 mM glucose (Paper IV) while L. mutabilis (1 mg/ml) treatment 
was done in 5 and 11 mM glucose (Paper V).  Non-treated cell controls were 
cultured in equivalent glucose concentrations. 
The total RNA of treated and non-treated cells was extracted using a silica membrane 
spin column-based RNeasy mini kit, according to the manufacturer’s protocol. The 
RNA purity and concentration were determined with a Nanodrop. 1 μg of RNA 
was transcribed to cDNA using the High –Capacity cDNA Reverse Transcription 
Kit. The relative expression was determined by quantitative real-time polymerase 
chain reaction (qRT-PCR) of target genes and expressed as 2-ΔCT to housekeeping 
gene and fold change as 2-ΔΔCT comparing uninfected to non-treated control [133, 
134, 198]. The following probes were used (Table 2):
Table 2. Probes used to evaluate gene expression of adhesion and invasion mol-
ecules in uroepithelial cells
Gene Probe
UPK1A (uroplakin 1a) Hs00199638_m1, Applied Biosystems [133]
ITGB1 (β-integrin) Hs00559595_m1, Applied Biosystems [133, 134]
CAV1 (Caveolin 1) Hs00184697_m1, Applied Biosystems [134, 199, 200]
GAPDH 4326317E [133]
18s Hs03003631 g1 [201]
3.4.8 Gene expression of antimicrobial peptides 
Antimicrobial peptides are molecules that prevent infections by disruption of bacte-
ria membrane, killing extracellular and intracellular bacteria. Thus, as uroepithelial 
cells produce antimicrobial peptide as a mechanism of innate immune response, 
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we explored the induction of antimicrobial peptides by treatment of uroepithelial 
cells culture with A. caudatus or L. mutabilis. The gene expression of antimicro-
bial peptides, cathelicidin LL-37, psoriasin, human 𝛽-defensin 2 and RNase7, 
were measured in 5637 cells treated with A. caudatus (10 mg/ml; 11mM glucose, 
hyperglycemic) (Paper IV) or L. mutabilis (1 mg/ml; 5mM, normo-glycemic and 
11 mM, hyperglycemic) (Paper V) after 24 h of treatment by qRT-PCR,  following 
the procedure described before. The following probes and primers were used [134, 
198] (Table 3):
Table 3. Probes and primers used to evaluate gene expression of antimicrobial 
 peptides in uroepithelial cells
Gene Probe/Primers
CAMP (cathelicidin LL-37) Hs00189038 m1 [133, 198]
S100A7 (psoriasin) Hs00161488 m1 [133, 198]
DEFB4A (human 𝛽-defensin 2) F (5’ - ccctttctgaatccgc) R (5’ - gagggtttgtatctcct) [202]
RNASE7 (RNase 7) F (5’- ggagtcacagcacgaagacca) R  
(5’ - catggctgagttg- catgcttga) [203]
ACTB (β-actin) F (5’ -aagagaggcatcctcaccct) R (5’ -tacatcgctggggtgttg) [204]
3.4.9 Protein expression by immunofluorescence staining 
To correlate gene expression with protein synthesis of antimicrobial peptides, 
protein expression was determined by immunofluorescence staining. This method 
provides information about the expression and location of a specific protein in 
the cell. It uses specific primary antibodies that target the specific molecule, 
then a fluorophore-conjugated secondary antibody is used to visualize the initial 
 detection [205]. Briefly, 5637 cells grown on glass coverslips were treated L. 
mutabilis (1 mg/ml) for 24 h in both normoglycemic (5 mM) and hyperglycemic 
(11mM) conditions. After treatment, cells were fixed with 4% paraformaldehyde 
during 30 min at room temperature; to allow antibody entrance, cell membrane 
was permeabilized with 0.1% triton- X-100 in PBS, and blocking was done using 
5% BSA in PBS for 30 min at room temperature [198]. For immune staining, cells 
were incubated with primary antibodies against RNase7 (1:200) or uroplakin1a 
(1:200) diluted in 1:1 ratio of 1 X PBS with 0.1% Tween 20 (PBS-T) and 5% BSA 
in PBS, overnight at 4°C. After incubation, cells were washed with 1 X PBS-T and 
incubated with secondary detection antibody Alexa Fluor–conjugated antibody 
(1:500) during 1 h at room temperature. Slides were mounted in Fluoromount G 
and were analyzed with a Leica SP5 confocal microscope using 63x oil immer-
sion objective [198] (Paper V). 
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3.4.10 Biofilm formation assay 
To investigate the effect of L. mutabilis extract on bacterial biofilm formation, the 
crystal violet microtiter plate assay was used. This assay is an indirect method for 
bacterial adhesion and thickness of biofilm, and the method to measure is based 
on the matrix staining including living and dead cells [206]. E. coli No. 12 was 
grown at 37°C with 5% CO2 for 72h in LB broth without salt, supplemented with 
either 5 or 11 mM glucose, or as controls with no additional glucose, and treated 
with L. mutabilis (0.4 – 1 mg/ml). At indicated time point, the planktonic cells 
were removed by washing with phosphate-buffered saline and bacteria that formed 
biofilm were stained with crystal violet (3%) [133]. 
After removing crystal violet and washing, a solution of acetone and ethanol was 
used to dissolve the remaining crystal violet and the OD was measured using 
spectrophotometry at 570 nm (Paper V).
3.4.11 Statistical Analysis
Graph Pad Prism Software, version 6.0 was used. For antidiabetic studies, sig-
nificance was analyzed by two-way analysis of variance (ANOVA) and paired 
Student’s t-test. Correction of multiple testing was done using Bonferroni’s Post 
Hoc Test. (Papers I, II and III) [174, 182]. For antibacterial studies, Student’s 
unpaired t-test, Mann Whitney U test, and one-way ANOVA, were used [133, 134, 
198] (Papers IV and V).
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4 RESULTS AND DISCUSSION
4.1 Antidiabetic Studies (Papers I, Paper I and II)
This part of the thesis project aims to evaluate the antidiabetic effect. First, the 
results of the glycemia-reducing screening in Swiss mice, are part of the Paper I. 
Further, the active plant extracts, A. caudatus and L. mutabilis, were evaluated in 
the T2DM animal model GK rats and its respective healthy control, W rats; results 
of A. caudatus evaluations are included in Paper II, while results of L. mutabilis 
evaluations are included in Paper III.
4.1.1 Paper I. Glycemia-reducing effects of Bolivian  
nutraceutical plants 
Among the three kinds of extracts, both in the screening and OGTT the hydroetha-
nolic extracts (EtOH70) of A. caudatus, C. quinoa, L. mutabilis and S. sonchifolius 
showed major and significant glucose-reducing effect. 
Extract preparation is an important factor that should be considered to assess the 
plant effects [207, 208], thus we found that 70% of ethanol in distilled water solu-
tion enriched the extract with organic compounds that could be responsible for 
the observed effect. The phytochemical qualitative characterization of EtOH70 
extracts detected high contents of anthocyanidins in A. caudatus, followed by 
phenolic compounds found also in C. quinoa; flavonoids and coumarins were 
found in C. pallidicaule and high contents of alkaloids in L. mutabilis; coumarins 
and anthocyanidins were found in S. sonchifolius, constituents reported in other 
studies with same species or related species which belong from same family [167]. 
The exploration of the effect of EtOH70 extracts on in vitro insulin secretion, 
performed in batches of mice pancreatic islets showed that extracts have different 
effects on glucose homeostasis since only extracts of A. caudatus, L. mutabilis 
and C. quinoa increased insulin release (Figure 8). 
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Figure 8. A. caudatus, L. mutabilis and C. quinoa EtOH70 extracts stimulates  insulin 
release. Swiss mice islets were incubated in KRB (3.3 mM or 16.7 mM glucose) plus EtOH70 
extracts of A. caudatus (A), L. mutabilis (B) and C. quinoa (C). Data are presented as 
means ± SEM, of duplicates from three independent experiments. *p< 0.05, ** p<0.01, 
*** p<0.001, **** p<0.0001, compared to negative control.
A. caudatus seeds water decoction [209] and methanolic extract [210] have been 
reported to inhibit α-amylase. However, in our study A. caudatus stimulated insulin 
release in high glucose conditions (16.7 mM), but not in low glucose conditions, 
that could make A. caudatus ideal for potential therapeutic use. 
L. mutabilis reduces glycemia in patients with intolerance to glucose [211] and in 
patients with type 2 diabetes, due to the alkaloid content [212]. C. quinoa inhibits 
the α-glucosidase with no effect on pancreatic α–amylase [213] and in high fructose-
treated Wistar rats, reduced the lipid profile and glycemia [214]. In our hands, L. 
mutabilis and C. quinoa stimulated insulin release in both low and high glucose 
conditions, and their effect was concentration-dependent. Thus, their effects were 
similar to those of sulphonylurea drugs [89]. None of the hydroethanolic extracts 
showed acute in vivo toxicity and in vitro experiments used concentrations lower 
than the media cytotoxic concentration.
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In summary, we provide information about the glycemia-reducing properties of 
plants under study in non-fasted and in mice with induced-hyperglycemia; this effect 
is partially mediated by the stimulation of insulin secretion in islets treated with 
A. caudatus, L. mutabilis and C. quinoa. Results of screening studies  confirmed 
literature reports and oriented further experiments to explore the effect on insulin 
secretion in a T2DM model.
4.1.2 Paper II. Amaranthus caudatus stimulates insulin secretion 
in Goto-Kakizaki rats, a model of Diabetes Mellitus type 2
In vivo evaluations showed that a single oral administration of A. caudatus (2000 mg/
kg b.w.) hydroethanolic extract augmented serum insulin during the first 30 min 
of the OGTT in GK rats 1.46 fold and in W rats1.64 fold and the glucose toler-
ance improved with a reduction of the AUC of the glucose curve of 24% in GK 
rats and 40% in W rats. 
In GK rats, the oral treatment with A. caudatus (1000 mg/kg b.w.) during 21 days 
reduced the non-fasting glycemia and improved the glucose tolerance with a reduc-
tion of the AUC of 24% in GK rats, and by increasing serum insulin levels 2.3-fold 
at day 20. In W rats the AUC was reduced 45% and serum insulin increased  2.2-fold, 
with no signal of hypoglycemia. Besides, A. caudatus reduced the percentage of 
HbA1c, 19.8 % in GK rats (Figure 9A) and 10.7% in W rats (Figure 9C), evidence 
of the A. caudatus contribution to long-term glycemic control. The augmented 
serum insulin suggests that A. caudatus affects insulin release, as proved by the 
improvement of glucose-dependent insulin secretion in pancreatic islets isolated 
from treated GK (Figure 9B) and W rats (Figure 9D). 
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Figure 9. A. caudatus oral treatment during 21 days reduces the plasma HbA1c and 
improved insulin secretion in pancreatic islets. HbA1c measured in time cero, 10 and 20 
days in GK rats (A) and in W rats (C) (n = 6). Pancreatic islets isolated at the endpoint 
from GK rats (B) and W rats (D) were cultured in low and high glucose (n = 4). Data are 
presented as means ± SEM and significances * p < 0.05, **** p < 0.0001 compared to 
placebo group; ## p < 0.01, compared to values from the same group.
Previous reports found that a methanolic extract of A. caudatus entire plant and 
methanolic extract of seeds inhibit the α-amylase activity [210, 215]. In SZT-diabetic 
rats, the methanol extract of A. caudatus leaves decreases glycemia [216]. A  similar 
effect on glycemia reduction is attributed to other species from Amaranthus genus 
[217-221]. Our results support the traditional use and the scientific evidence avail-
able about the effect on glycemia reduction and the other parameters  measured 
explain the effect by an improvement on β-cell insulin release, i.e. a primary 
metabolic defect in GK rats [9]. According to the phytochemical analysis, the A. 
caudatus extract has constituents in concordance to reports of A. caudatus or other 
species from the Amaranthus family [216, 222, 223]. Besides, sub-acute toxicity 
studies did not show a toxic effect in tested conditions.
In vitro studies showed that A. caudatus stimulated the insulin secretion in batch-
incubated islets; with a concentration-dependent effect observed in both GK and 
W rat in high glucose conditions. In low glucose conditions, a significant but lower 
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effect was observed (Figure 10A-C). Furthermore, A. caudatus enhanced the basal 
insulin secretion in perifused islets in low glucose and was further stimulated in 
high glucose conditions, but when the AUC was calculated, significant differences 
were only observed in W rats. Interestingly, A. caudatus effect was reversible 
since insulin secretion returned gradually to the basal level when the extract was 
removed from the perifusion buffer (Figure 10B-D). These results are evidence 
that A. caudatus does not cause any toxic effect on β-cells followed by insulin 
leakage; a similar effect has been described for isolated compounds from other 
plant extracts [174, 182, 224]. 
Figure 10. A. caudatus stimulates the in vitro insulin secretion in batch and perifused 
pancreatic islets. Insulin secretion in presence of A. caudatus (5–20 mg/ml) was evalu-
ated in GK rat islets (A) and W rat islets (C) (n = 8). The AUC of the insulin secretion in 
perifused islets with A. caudatus (20 mg/ml) form GK (B) and Wistar (D) rats from time 
0 to 14 min (3.3 mM glucose) and time 16 to 30 min (16.7 mM glucose) (n=4). Data are 
presented as means ± SEM and significances *p<0.05,**p<0.01,***p<0.001, **** p < 
0.0001 compared to untreated islets.
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The exploration of the mechanism of action showed that A. caudatus (20 mg/ml) 
effect is glucose-independent that mainly involves PKA and PKC systems, and 
partially the L-type Ca2+ channels opening and G-coupled exocytosis (Table 4). 
Table 4. Effect of inhibitors of insulin secretion pathway, Nifedipine (Nf), H-89 
 dihydrochloride hydrate (H89), Claphostine C (Cal-C) and Pertussis Toxin (Ptx) in 
pancreatic islets from GK and W rats. 
GK rats W rats
Glucose   3.3 mM   16.7 mM   3.3 mM   16.7 mM
Conditions
None 2.60 ±0.37 12.18± 0.66 6.88±0.79 35.05±2.79
A. caudatus (20 mg/ml) 15.50 ±0.85 92.75±5.82 38.77±3.79 164.48±4.65
Nf (10 μM) 2.82± 0.34 7.97±0.75 4.17±0.24 14.47±1.28
A. caudatus (20 mg/ml) + Nf  
(10 μM)
10.55±1.01 57.48±3.36**** 21.71±2.17** 95.57±8.72****
H89 (10 μM) 4.33±0.53 6.69±0.49 10.97±1.17 19.63±1.72
A. caudatus (20 mg/ml) + H89        
(10 μM)
6.94±0.58**** 17.85±1.59**** 9.79±1.58**** 19.10±1.30****
Cal-C (1.5 μM) 3.14±0.33 4.23±0.52 7.07±0.54 15.74±1.69
A. caudatus (20 mg/ml) + Cal-C   
(1.5 μM)
4.48±0.34**** 16.45±0.74**** 13.04±0.60**** 23.53±2.48****
Ptx (100 ng/mL) 2.48±0.30 3.50±0.26 2.47±0.31 3.50±0.26
A. caudatus (20 mg/ml) + Ptx  
(100 ng/ml)
6.68±0.33** 67.22±3.13*** 29.94±1.06*** 146.42±6.87***
Insulin concentration (μU/islet) are presented as means ± SE (n = 8) of A. caudatus 
plus each inhibitor. 
*p< 0.05, ** p<0.01, *** p<0.001, **** p<0.0001 compared to A. caudatus alone.
The activation of PKA and PKC promotes the increase of highly sensitive to 
Ca2+ insulin vesicles [192, 225], a mechanism that might explain the increase of insu-
lin release in presence of A. caudatus. Additionally, the intracellular Ca2+ increase 
and the exocytosis mediated by G-proteins [226] are partially required for A. 
 caudatus effect during the final stages of insulin release. 
The A. caudatus inhibition mediated by Ptx might be related to the inhibition of other 
G-proteins, that is finally required for kinases activation; Gs protein that mediates 
PKA activation by the activation of adenylate cyclase and Gq that mediates PLC 
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activation, i.e. events that finally activates PKC [225, 226]; thus, the exploration 
of the role of those G-proteins in A. caudatus effect has to be further evaluated. 
The membrane depolarization of β-cells was not a primary mechanism attributed 
to A. caudatus since a high concentration of KCl plus diazoxide did not inhibit 
the A. caudatus effect. Moreover, no effect was observed on glucose uptake in 
primary adipocytes. 
4.1.3 Paper III. Lupinus mutabilis extract exerts anti-diabetic 
effect by improving insulin release in type 2 diabetic 
Goto-Kakizaki rats
A single oral administration of L. mutabilis hydroethanolic extract (2000 mg/kg 
b.w.) improved glucose tolerance, with a reduction of 25% of the AUC of glucose 
under the OGTT and augmented serum insulin 2.08-fold, in GK rat; a similar effect 
was observed in W rats. The effect was dose-dependent and the increment in serum 
insulin started already after the extract administration, meaning that L. mutabilis 
effect is glucose-independent. Interestingly, the effect did not induce hypoglycemia, 
since glycemia at the end of the test were not lower than fasted values. 
The long-term treatment with L. mutabilis (1000 mg/kg b.w.) improved glucose 
metabolism, evidenced by a reduction of the AUC of glucose during the OGTT in 
both types of rats, and a significant reduction of 12% of the non-fasting glucose 
observed only in GK rats, meaning that L. mutabilis controlled high glycemia 
levels present in GK rats [9], a condition not present in W rats. Additionally, the 
HbA1c percentage was reduced, and serum insulin was increased (Figure  11A-C). 
Moreover, L. mutabilis improved the insulin release in pancreatic islets from treated 
animals in low and high glucose conditions, suggesting that the glycemia control 
is secondary to the promotion of β-cell function (Figure 11B-D). 
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Figure 11. L. mutabilis oral treatment during 21 days reduces the plasma HbA1c and 
improved insulin secretion in pancreatic islets. HbA1c measured in time cero, 10 and 
20 days in GK rats (A) and W rats (C) (n = 6). Pancreatic islets isolated at the endpoint 
from GK rats (B) and W rats (D) were cultured in low and high glucose (n = 4). Data are 
presented as means ± SEM and significances * p < 0.05, **** p < 0.0001 compared to 
placebo group; ## p < 0.01, compared to values from the same group. 
These findings support the use of daily consumption of components present in 
L. mutabilis extract to control hyperglycemia in diabetic patients [211, 212]. 
Traditionally, the water in which L. mutabilis seeds are washed controls  glycemia 
after meals [227]. Our results support the L. mutabilis acute mechanism that 
 augments serum insulin in a glucose-independent way, and its constituents might 
have a rapid absorption to target the pancreas to stimulate insulin release. 
In vitro experiments showed that L. mutabilis has a glucose-independent effect 
on insulin release in GK rats, while W rats islets were more sensitive (Figure 12 
A-C). Interestingly, the highest L. mutabilis concentration used showed less effect; 
 possible due to the interaction of inhibitory compounds or to the possible toxicity of 
the alkaloid content, present in the extract [228]. However, the in vitro cytotoxicity 
studies showed that tested concentrations were not toxic in the time period used in 
our experiments. L. mutabilis improved insulin release in perifused GK islets, the 
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effect started gradually in low glucose and was enhanced in high glucose; when 
the extract was removed, insulin secretion went back to basal levels, evidence that 
L. mutabilis does not alter β-cell structure or function (Figure 12B-D).
Figure 12. L. mutabillis stimulates the in vitro insulin secretion in batch and perifused 
pancreatic islets. Insulin secretion in presence of L. mutabillis (5–15 mg/ml) was evalu-
ated in GK rat islets (A) and W rat islets (C) (n = 8). The AUC of the  insulin secretion in 
perifused islets from GK (B) and Wistar (D) rats from time 0 to 14 min (3.3 mM glucose) 
and time 16 to 30 min (16.7 mM glucose) (n=4). Data are presented as means ± SEM and 
significances *p<0.05,**p<0.01,***p<0.001, **** p < 0.0001 compared to untreated islets.
In vitro evaluation of the mechanism of action using blocking components of the 
insulin secretion pathway showed that L. mutabilis effect modulates initial steps 
of insulin secretion pathway i.e. the closure of K-ATP channels and the opening of 
L-type Ca2+ channels. Several reports describe the effects on stimulation of insulin 
release of different Lupinus species, mainly due to their alkaloid content i. e. spar-
teine, lupanine and synthetic derivatives, an effect that is inhibited by diazoxide 
[229-232]; while L. mutabilis modulation of voltage-dependent Ca2+ channels that 
might trigger exocytosis of insulin-containing granules, has not been reported 
before (Table 5).
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Table 5. Effect of inhibitor of insulin secretion pathway, Diazoxide (Dx) and 
Nifedipine (Nf) in pancreatic islets from GK and W rats. 
GK rats W rats
Glucose    3.3 mM    16.7 mM    3.3 mM    16.7 mM
Conditions
none 3.96±0.46 12.70±0.72 7.30±1.24 38.51±2.97
L. mutabilis (10 mg/ml) 7.21±0.46 104.71±6.96 27.78±1.80 103.33±4.94
Dx (0.25 mM) 2.93±0.48 10.58±1.05 3.74±0.19 18.68±0.69
Dx (0.25 mM) + KCl (50 mM) 6.70±0.60 40.22±1.78 9.27±1.07 81.82±2.33
L. mutabilis (10 mg/ml) + Dx 
(0.25 mM)
17.17±1.91 60.36±3.25**** 20.49±1.20**** 53.08±4.33****
L. mutabilis (10 mg/ml) + Dx 
(0.25 mM) + KCl (50 mM)
12.03±0.54 47.68±2.13**** 34.07±2.62**** 61.62±3.43****
Nf (10 μM) 4.76±0.57 8.44±0.65 4.11± 0.29 17.42±1.10 
L. mutabilis (10 mg/ml) + Nf 
(10 μM)
18.31±1.33 31.17±3.14**** 18.21±1.89 39.77±1.53****
Insulin concentration (μU/islet) are presented as means ± SE (n = 8) of A. caudatus 
plus each inhibitor.
*p< 0.05, ** p<0.01, *** p<0.001, **** p<0.0001 compared to A. caudatus alone.
The results of the phytochemical analysis are in concordance with the literature, 
the hydroethanolic crude extract main components are alkaloids [212, 229, 233, 
234]; therefore, the observed effect might be attributed to the presence of alkaloids. 
Since alkaloids found in Lupinus species are reported as neurotoxins [235], toxicity 
studies were conducted. In vivo sub-acute toxicity showed that tested dose (1000 
mg/kg b.w.) did not alter hematological, biochemical or behavior parameters, and 
in vitro cytotoxicity evaluations showed that used concentrations were not toxic. 
Furthermore, L. mutabilis effect in GK rat islets involves the activation of both 
the PKA and PKC, and G-protein mediated exocytosis, only in high glucose. In 
W rat islets, those systems are involved in both low and high glucose conditions. 
PKA and PKC activation promote the increase of highly sensitive to Ca2+ insulin 
vesicles [192, 225] and G proteins are involved in the last steps of insulin release 
by membrane fusion mediated by SNARE proteins; thus both events are strongly 
modulated by L. mutabilis (Table 6). 
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Table 6. Effect of inhibitor of insulin secretion pathway, H-89 dihydrochloride hydrate 
(H89), Calphostine C (Cal-C) and Pertussis Toxin (Ptx) in pancreatic islets from GK 
and W rats. 
GK rats W rats
Glucose 3.3 mM 16.7 mM 3.3 mM 16.7 mM
Conditions
None 3.96±0.46 12.70±0.72 7.30±1.24 38.51±2.97
L. mutabilis (10 mg/ml) 7.21±0.46 104.71±6.96 27.78±1.80 103.33±4.94
H89 (10 μM) 4.33±0.53 6.69±0.49 10.96±1.17 19.63±1.72
L. mutabilis (10 mg/ml) + H89 
(10 μM)
4.44±0.40 13.86±1.0**** 11.33±0.72**** 35.31±1.51****
Cal-C (1.5 μM) 3.14±0.33 4.23±0.51 7.07±0.54 15.74±1.70
L. mutabilis (10 mg/ml) + Cal-C 
(1.5 μM)
12.86±0.57 30.57±1.54**** 25.64±1.06* 63.07±2.65****
Ptx (100 ng/mL) 2.47±0.30 3.50±0.26 2.52±0.32 3.67±0.34
L. mutabilis (10 mg/ml) + Ptx 
(100 ng/ml)
3.11±0.30 7.37±0.92**** 16.74±0.94* 38.42±2.67****
Insulin concentration (μU/islet) are presented as means ± SE (n = 8) of A. caudatus 
plus each inhibitor. 
*p< 0.05, ** p<0.01, *** p<0.001, **** p<0.0001 compared to A. caudatus alone.
4.1.4 Graphical summary of Antidiabetic effect
A. caudatus and L. mutabilis hydroethanolic extracts effects on insulin secretion 
modulate certain points of the insulin secretion pathway with punctual differ-
ences on critical events, a summary of the proposed mechanism for both extracts 
is shown in figure 13.
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Figure 13. Mechanisms of A. caudatus and L. mutabilis on insulin secretion. Critical 
points along the insulin secretion pathway modulated by A. caudatus (red arrows) and L. 
mutabilis (blue arrows). Intensity of arrows is related with the relevance of each  specific point. 
4.2 Antibacterial Activity Studies (Papers IV and V)
UTIs are frequent infections in diabetic patients and maybe promoted as a com-
plication of glucose imbalance and by a defect in the immune response [236]. The 
globally increasing antibiotic resistance is a threat to successful treatment of the 
patient. Therefore, the search for new strategies to prevent or treat those infec-
tions is needed. In this part of the study, we explored the same hydroethanolic 
extracts of A. caudatus (Paper IV) and L. mutabilis (Paper V) as above, for the 
possible impact on UTI.
4.2.1 Paper IV. Amaranthus caudatus extract inhibits the 
 invasion of E. coli into uroepithelial cells 
A. caudatus hydroethanolic extract did not show any direct antibacterial effect. 
The results are contrary to studies using another Amaranth species i.e. Amaranth 
hybridus [237] and Amaranthus retraflexus [238] which have a direct antibacterial 
effect against ESBL-producing E. coli. isolates. 
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The exploration of the relationship between bacteria and host during infection is 
another approach to test further activities of medicinal plants when the direct anti-
bacterial effect has not been reported by medicinal plants [239, 240]. The impact 
of A. caudatus on the host-bacteria interaction was investigated in uroepithelial 
cells pre-treated with A. caudatus for 24 hours. We sought to study the possible 
protection against the initial stages of the infection process, adhesion and inva-
sion. The tested concentrations did not exert any cytotoxic effects. A. caudatus 
treatment (10 mg/ml), significantly reduced bacterial adhesion of E. coli #12 and 
the ESBL producing E. coli while no effect was observed on invasion. A similar 
effect on bacterial adhesion was reported for other medicinal plants, Citrus reticu-
lata reduces bacterial invasion [134]. Clinopodium bolivianum inhibits bacterial 
adhesion, which was attributed to the flavonoids content [133]. The phytochemi-
cal analysis of A. caudatus revealed minor amounts of polyphenols as a part of 
its constituents, among them flavonoids are chemicals that have been related to 
decreased adherence of UPEC to uroepithelial cells [241, 242].
Uroepithelial umbrella cells express surface glycoprotein UPIa that mediates 
bacterial adhesion by interaction with the subunit FimH of the type 1 fimbriae 
[58, 243], its reduction may, therefore, interfere with UPEC binding [244, 245]. 
The treatment of non-infected T24 cells with A. caudatus decreases UPIa gene 
expression after 24 h, this reduction is still observed during the infection process 
in the presence of A. caudatus, resulting in decreased E. coli adhesion. It has been 
reported that upon infection, the interaction between bacteria and cell receptors, 
triggers signal transduction that increases UPIa gene expression [52, 60]. Thus, the 
A. caudatus effect might interfere with the bacterial-induced signal transduction 
that promotes bacterial adhesion. A similar reduction was reported for Clinopodium 
bolivianum [133].
During the bacterial invasion process, β1-integrins and caveolin-1 proteins interact 
with FimH to promote UPEC invasion of bladder epithelial cells [57, 58]. In our 
study, A. caudatus pretreated T24 cells reduced gene expression of caveolin-1, both 
in non-infected and infected cells, while β1 integrin expression was not affected. 
Caveolin-1 proteins are located in the lipid rafts, a cell membrane domain which is 
responsible for the transduction of external signals [57]. The lipid rafts have also 
been reported to influence bacterial invasion through endocytosis [54]. Therefore, 
a reduced expression of caveolin-1 mediated by A. caudatus might disrupt bacterial 
infection. The invasion process allows the establishment of IBCs, which  promotes 
UPEC persistence [52], although bacteria, often phenotypically changed, can be 
released and infect nearby cells. It is, therefore, possible that A. caudatus might 
reduce the risk of recurrence of UTI [58, 246]. Finally, we further explored the 
expression of antimicrobial peptides, but we did not observe any effect of the 
tested antimicrobial peptides. 
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The strategy to prevent infection is an approach that is currently being explored, 
using vaccines to block FimH [46, 247]. Mannosides that mimic the natural receptor 
for type 1 pili specifically bind UPEC [248] and medicinal herbs may act on the 
host cells having similar result [48]. Therefore, results of A. caudatus treatment 
contribute to the promising strategies to prevent infection UPEC infection. Further 
studies are required to explore A. caudatus effect using in vivo UTI infection model. 
4.2.2 Paper V. Lupinus mutabilis Edible Beans Protect against 
Bacterial Infection in Uroepithelial Cells
To further broaden our search for possible alternative treatment strategies, we 
investigated the edible bean L. mutabilis. We did not observe any direct antibac-
terial effect, on uropathogenic bacteria when testing L. mutabilis hydroethanolic 
extract, up to 125 mg/ml. Then, we explored the indirect effect on the initial steps 
of bacterial infection. 
To rule out the toxic effect on the uroepithelial cells, we explored the viability 
of T24 and 5637 cells in the presence of L. mutabilis extract (1 mg/ml). After 24 
h of exposure, the viability of treated cells was similar to untreated cell (99%), 
and when the concentration increased up to 20 mg/ml, viability was still around 
80%. Moreover, following prolonged exposure of L. mutabilis up to 72 h, did not 
affect the cell viability which similar as untreated cells. We, therefore, conclude 
that there was no effect on the cell cycle or the metabolism, measured by XTT 
assay. Interestingly, studies have reported toxicity of alkaloids in L. mutabilis 
[235]. In our in vitro model, the concentrations were, however, not high enough 
to induce toxic effects.
We then explored the indirect effect on the initial steps of bacterial infection to 
the host. When investigating the effect on bacterial infection on uroepithelial 
cells, T24, we treated the cells with L. mutabilis (1 mg/ml), during 24 h prior to 
infection, and demonstrate reduced UPEC adherence. To confirm this finding, we 
tested other uropathogenic Gram-negative bacteria, like, ESBL-producing E. coli, 
K. pneumoniae, MDR K. pneumoniae, P. mirabilis and Gram-positive bacteria like 
S. saprophyticus, in both normal and high glucose conditions adhesion of men-
tioned bacteria was reduced, while adhesion of P. mirabilis was reduced only in 
normal glucose; the invasion process of all bacteria strain was not inhibited. The 
inhibition of bacterial adhesion observed in high glucose (11mM) indicates that 
L.mutabilis may protect against UPEC in hyperglycemic conditions observed in 
T2DM patients. Even though E. coli is the main microorganism responsible for 
UTI, other bacteria can also cause this infection [50] thus, L. mutabilis prevented 
adhesion to uroepithelial cells not only of Gram-negative but also Gram-positive 
bacteria, further studies to explore the specific events during bacterial adhesion 
need to be performed, since bacteria have their specific mechanism of infection. 
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Moreover, since L. mutabilis prevents adhesion of ESBL and MDR strains, the 
extracts might provide an alternative or complementary treatment strategy, espe-
cially to antibiotic-resistant bacteria. 
To explore the changes induced by L. mutabilis in host cells, we evaluated the 
expression of UPIa. In our study, L. mutabilis down regulated UPIa gene and 
protein expression in 5637 cells, treated during 24 h, prior to infection. The effect 
was observed both in normal and high glucose conditions. In parallel, expression 
of molecules important in the bacterial invasion was also evaluated, Caveolin-1 
and β1-integrin, but no changes were observed. These findings support our initial 
results where only the adhesion process was inhibited. L. mutabilis effect observed 
in both normal and high glucose concentrations, i.e. a condition that is similar to 
what is observed in diabetic patients, where they present glycosuria, might repre-
sent a promising product to prevent UTI in those individuals.
Interestingly, L. mutabilis up-regulated the AMP RNase 7 gene expression and 
 protein levels, both in low and high glucose conditions, while no effect was 
observed on LL-37 or human 𝛽-defensin 2. AMPs inhibit bacterial infection due 
to killing extra and intracellular bacteria by disruption of bacterial membrane 
[71]. RNase 7 is an AMP normally expressed in uroepithelial cells, where it has 
a bactericidal effect against Gram-negative and positive bacteria, including the 
multidrug-resistant strains [78]. Thus, we can conclude that L. mutabilis reduces 
the number of infecting bacteria due to bacterial lysis induced by RNase7. The 
remaining viable bacteria are prevented to adhere to the uroepithelium, because 
of the reduction of UPIa. This effect might be important to control UTI in the 
context of glycosuria present in diabetic patients. The high prevalence of UTI in 
diabetic patients is partly explained by the impairment of antimicrobial peptides 
function, as RNase 7 is released in an insulin dependent manner [78, 203]. In this 
context, L. mutabilis might offer an alternative or adjuvant strategy to prevent 
UTI in diabetic patients. 
Moreover, L. mutabilis (1 mg/ml) inhibited E. coli No. 12 biofilm formation, with 
no impact on bacterial growth, although the effect was observed only in normal 
glucose conditions. The ability of UPEC to form biofilm, allows bacterial per-
sistence and difficulties to successful treatment and risk of recurrent infections 
[249]. Similar results are attributed to herbal extracts [135] and components as to 
polyphenols [242], sugars and fructose that suppress mannose-sensitive fimbrial 
adhesins [250]. Moreover, biofilm inhibition was observed with sub-inhibitory 
concentrations of LL-37 [82]. Biofilm inhibition is one mechanism that contrib-
utes to prevent recurrent infection [61], pro-inflammatory cytokines are related 
to biofilm inhibition which promotes planktonic growth [49]. Thus, L. mutabilis 
effect on cytokine expression and the exploration of the specific mechanisms 
behind the biofilm formation are needed.
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4.2.3 Graphical summary of the antibacterial effect
Figure 14. Mechanisms of A. caudatus and L. mutabilis antibacterial effect. Points along 
the UPEC infection pathways modulated by A. caudatus are indicated in red arrows; a 
decrease of UPIa and caveolin-1 gene expression. Effects of L. mutabilis are indicated 
in blue arrows;  decrease of UPIa gene and protein expression, upregulation of gene and 
protein expression of RNase7, and inhibition of biofilm formation. 
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5 CONCLUSIONS
1. In the screening studies, the hydroethanolic extract of all plants tested showed 
a strong glycemia-reducing effect in normoglycemic Swiss mice. The effect 
involved the stimulation of insulin secretion in islets treated with A. caudatus, 
L. mutabilis and C. quinoa. 
2. Based on screening studies, we further selected to continue the antidiabetic 
studies. A. caudatus and L. mutabilis improved glucose tolerance in the diabetic 
GK rat model, effects secondary to the long-term glycemia control reflected 
as reduction of the Hb1Ac and increase of insulin secretion. The mechanisms 
behind these effects differ somewhat between extracts. A.  caudatus stimu-
lated insulin secretion using protein kinases A and C activation, and partially 
involving intracellular calcium increase and G protein-coupled exocytosis. 
The L. mutabilis effect depended on L-type calcium channels, PKC and PKA 
systems, G protein-coupled exocytosis and was partially mediated by K-ATP 
channels of the β-cells. Thus, both extracts are promising candidates for the 
treatment of type 2 diabetes mellitus.
3. A. caudatus and L. mutabilis extracts might contribute to the prevention of 
common infections like UTI caused by uropathogenic E. coli. A. caudatus 
protects the uroepithelium from invading bacteria, including drug-resistant 
strains by downregulating the membrane proteins, uroplakin1a and caveolin-1, 
which contribute to adhesion and invasion in uroepithelial cells. L. mutabilis 
further prevents bacterial adhesion, irrespective of glucose concentrations. This 
effect is explained by downregulation of the adhesion molecule, uroplakin-1a 
and up-regulation of the antimicrobial peptide RNase7. Moreover, L. mutabilis 
inhibited bacterial biofilm. These results are important findings to understand 
the interaction between the host and the bacteria in the pathogenesis of UTI. 
It may also serve as a possible alternative preventive strategically approach. 
In summary, our results provide evidence of the pharmacological activity of the 
plant extracts tested, supporting the nutraceutical potential of A. caudatus and 
L. mutabilis in the treatment of type 2 diabetes mellitus and hopefully also to 
prevent UTI in hyperglycemia, mimicking the diabetic condition.
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